Mechanisms of Ischemic Stroke in Cancer Patients

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions
StrokeCancer
Interventions
OTHER

Blood tests

"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."

OTHER

Transcranial Doppler Microemboli Detection Study

Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

New York-Presbyterian Hospital/Weill Cornell Medical Center, New York

All Listed Sponsors
collaborator

University of California, Davis

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT02604667 - Mechanisms of Ischemic Stroke in Cancer Patients | Biotech Hunter | Biotech Hunter